Topical administration of S. salivarius 24SMB-S. oralis 89a in children with adenoidal disease: a double-blind controlled trial.
Adenoids
Children
Otitis
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
23
05
2023
accepted:
04
09
2023
revised:
01
09
2023
medline:
9
2
2024
pubmed:
24
10
2023
entrez:
24
10
2023
Statut:
ppublish
Résumé
Chronic adenoiditis (CA) is generally sustained by some infectious foci mainly located within the nasopharynx or in the deep adenoidal pads and it is characterized by a complex interplay between bacterial species. The aim of this study was to assess the efficacy and safety of the topical nasal administration of a probiotic compound based on S. salivarius 24SMB and S. oralis 89a in children with CA in terms of reduction in: the number of acute adenoidal infections (primary outcome), and in the blockage of the nasopharynx space by hypertrophic adenoids (secondary outcome). A prospective, double-blind, 1:1 randomized controlled study was performed to test the effectiveness of a 90-day treatment with Rinogermina spray (DMD ITALIA s.r.l, Rome), 1 puff each nostril twice a day for 90 days, to nasal spray placebo in children with CA (in terms of number of acute exacerbations and blockage of nasopharynx space assessed after 90 days of treatment- T1, and 90 days later- T2). The final analysis was based on 152 children (males = 48.0%; mean age = 49.2 ± 14.1 months). Compared to the baseline, no significant differences in terms of number of acute exacerbations at T1 and T2 follow-up visits were detected in both groups. After treatment, a significant reduction in the blockage of nasopharynx space by hypertrophic adenoids (0.002 < p-value < 0.007) compared to the baseline was attested in the study group at T1 and T2, but not in the control group. Our findings document a positive effect of Rinogermina spray in achieving reduction in the blockage of nasopharynx space by hypertrophic adenoids, thus suggesting that its use into the integrated therapeutic management of children with CA could be of a certain utility. • Chronic adenoiditis in children results from an imablance in baterial homeostasis at the nasophaynx, with impairment in respiratory microbiota. • The modulatory effect of target transnasal bacteriotheray by means of S. salivarius has been considered in children with chronic adenoiditis in children with recurrent acute otitis media with preliminary positive results. • This randomized controlled study, specifically designed on a cohrt of children with chronic adenoiditis, documents a certain effectiveness of the probiotic treatment in achieving a reduction in the grade of adenoidal hypertropy, compared to placebo.
Identifiants
pubmed: 37874401
doi: 10.1007/s00431-023-05192-w
pii: 10.1007/s00431-023-05192-w
pmc: PMC10857951
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-294Informations de copyright
© 2023. The Author(s).
Références
Marseglia GL, Poddighe D, Caimmi D, Marseglia A, Caimmi S, Ciprandi G, Klersy C, Pagella F, Castellazzi AM (2009) Role of adenoids and adenoiditis in children with allergy and otitis media. Curr Allergy Asthma Rep. https://doi.org/10.1007/s11882-009-0068-4 . PMID: 19814919
doi: 10.1007/s11882-009-0068-4
pubmed: 19814919
Mansbach AL, Brihaye P, Casimir G, Dhooghe I, Gordts F, Halewyck S, Hanssens L, Lemkens N, Lemkens P, Leupe P, Mulier S, Van Crombrugge L, Van Der Veken P, Van Hoecke H (2012) Clinical aspects of chronic ENT inflammation in children. B-ENT.;8 Suppl 19:83–101
Drago L, De Vecchi E, Torretta S, Mattina R, Marchisio P, Pignataro L (2012) Biofilm formation by bacteria isolated from upper respiratory tract before and after adenotonsillectomy. APMIS. https://doi.org/10.1111/j.1600-0463.2011.02846.x
doi: 10.1111/j.1600-0463.2011.02846.x
pubmed: 22515296
Nazzari E, Torretta S, Pignataro L, Marchisio P, Esposito S (2015) Role of biofilm in children with recurrent upper respiratory tract infections. Eur J Clin Microbiol Infect Dis 34(3):421–429. https://doi.org/10.1007/s10096-014-2261-1 . Epub 2014 Oct 16 PMID: 25318897
doi: 10.1007/s10096-014-2261-1
pubmed: 25318897
Torretta S, Drago L, Marchisio P, Ibba T, Pignataro L (2019) Role of biofilms in children with chronic adenoiditis and middle ear disease. J Clin Med. https://doi.org/10.3390/jcm8050671 . PMID: 31086039
doi: 10.3390/jcm8050671
pubmed: 31382570
pmcid: 6723210
Drago L, Cappelletti L, De Vecchi E, Pignataro L, Torretta S, Mattina R (2014) Antiadhesive and antibiofilm activity of hyaluronic acid against bacteria responsible for respiratory tract infections. APMIS. https://doi.org/10.1111/apm.12254
doi: 10.1111/apm.12254
pubmed: 24698341
Torretta S, Marchisio P, Drago L, Baggi E, De Vecchi E, Garavello W, Nazzari E, Pignataro L, Esposito S (2012) Nasopharyngeal biofilm-producing otopathogens in children with nonsevere recurrent acute otitis media. Otolaryngol Head Neck Surg. https://doi.org/10.1177/0194599812438169 . Epub 2012 Feb 21.PMID: 22357644
Torretta S, Drago L, Marchisio P, Mattina R, Clemente IA, Pignataro L (2011) Diagnostic accuracy of nasopharyngeal swabs in detecting biofilm-producing bacteria in chronic adenoiditis: a preliminary study. Otolaryngol Head Neck Surg. https://doi.org/10.1177/0194599810394955 . PMID: 21493370
doi: 10.1177/0194599810394955
pubmed: 21493370
Torretta S, Drago L, Marchisio P, Gaffuri M, Clemente IA, Pignataro L (2013) Topographic distribution of biofilm-producing bacteria in adenoid subsites of children with chronic or recurrent middle ear infections. Ann Otol Rhinol Laryngol. https://doi.org/10.1177/000348941312200206 . PMID: 23534125
doi: 10.1177/000348941312200206
pubmed: 23534125
Pamer EG (2007) Immune responses to commensal and environmental microbes. Nat Immunol. https://doi.org/10.1038/ni1526 . PMID: 17952042
doi: 10.1038/ni1526
pubmed: 17952042
Folino F, Ruggiero L, Capaccio P, Coro I, Aliberti S, Drago L, Marchisio P, Torretta S (2020) Upper respiratory tract microbiome and otitis media intertalk: lessons from the literature..J Clin Med 9(9):2845. https://doi.org/10.3390/jcm9092845 . PMID: 32887458
Folino F, Fattizzo M, Ruggiero L, Oriano M, Aliberti S, Blasi F, Gaffuri M, Marchisio P, Torretta S (2021) Nasopharyngeal microbiota analysis in healthy and otitis-prone children: focus on history of spontaneous tympanic membrane perforation. Pediatr Infect Dis J. https://doi.org/10.1097/INF.0000000000002895
doi: 10.1097/INF.0000000000002895
pubmed: 33055502
Jensen A, Fagö-Olsen H, Sørensen CH, Kilian M (2013) Molecular mapping to species level of the tonsillar crypt microbiota associated with health and recurrent tonsillitis. PLoS One. https://doi.org/10.1371/journal.pone.0056418
Swidsinski A, Göktas O, Bessler C, Loening-Baucke V, Hale LP, Andree H, Weizenegger M, Hölzl M, Scherer H, Lochs H (2007) Spatial organisation of microbiota in quiescent adenoiditis and tonsillitis. J Clin Pathol. https://doi.org/10.1136/jcp.2006.037309
doi: 10.1136/jcp.2006.037309
pubmed: 16698947
Hilty M, Qi W, Brugger SD, Frei L, Agyeman P, Frey PM, Aebi S, Mühlemann K (2012) Nasopharyngeal microbiota in infants with acute otitis media. J Infect Dis. https://doi.org/10.1093/infdis/jis024
doi: 10.1093/infdis/jis024
pubmed: 22351941
Marchisio P, Santagati M, Scillato M, Baggi E, Fattizzo M, Rosazza C, Stefani S, Esposito S, Principi N (2015) Streptococcus salivarius 24SMB administered by nasal spray for the prevention of acute otitis media in otitis-prone children. Eur J Clin Microbiol Infect Dis. https://doi.org/10.1007/s10096-015-2491-x
doi: 10.1007/s10096-015-2491-x
pubmed: 26385346
Di Pierro F, Risso P, Poggi E, Timitilli A, Bolloli S, Bruno M, Caneva E, Campus R, Giannattasio A (2018) Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects. Minerva Pediatr. https://doi.org/10.23736/S0026-4946.18.05182-4
doi: 10.23736/S0026-4946.18.05182-4
pubmed: 29651835
Di Pierro F, Colombo M, Giuliani MG, Danza ML, Basile I, Bollani T, Conti AM, Zanvit A, Rottoli AS (2016) Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children.Eur Rev Med Pharmacol Sci 20(21):4601–4606
Gregori G, Righi O, Risso P, Boiardi G, Demuru G, Ferzetti A, Galli A, Ghisoni M, Lenzini S, Marenghi C, Mura C, Sacchetti R, Suzzani L (2016) Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag. https://doi.org/10.2147/TCRM.S96134
Tano K, Olofsson C, Grahn-Håkansson E, Holm SE (1999) In vitro inhibition of S. pneumoniae, nontypable H. influenzae and M. catharralis by alpha-hemolytic streptococci from healthy children.Int J Pediatr Otorhinolaryngol. https://doi.org/10.1016/s0165-5876(98)00174-8
La Mantia I, Varricchio A, Di Girolamo S, Minni A, Passali GC, Ciprandi G (2019) The role of bacteriotherapy in the prevention of adenoidectomy. Eur Rev Med Pharmacol Sci. https://doi.org/10.26355/eurrev_201903_17348
Karpova EP, Karpycheva IE, Tulupov DA (2015) Prophylaxis of chronic adenoiditis in the children. Vestn Otorinolaringol. https://doi.org/10.17116/otorino201580643-45
La Mantia I, Varricchio A, Ciprandi G (2017) Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for preventing recurrent acute otitis media in children: a real-life clinical experience. Int J Gen Med. https://doi.org/10.2147/IJGM.S137614
Burton JP, Chilcott CN, Wescombe PA, Tagg JR (2010) Extended safety data for the oral cavity probiotic Streptococcus salivarius K12. Probiotics Antimicrob Proteins. https://doi.org/10.1007/s12602-010-9045-4
Burton JP, Cowley S, Simon RR, McKinney J, Wescombe PA, Tagg JR (2011) Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol. https://doi.org/10.1016/j.fct.2011.06.038
Wilcox CR, Stuart B, Leaver H, Lown M, Willcox M, Moore M, Little P (2019) Effectiveness of the probiotic Streptococcus salivarius K12 for the treatment and/or prevention of sore throat: a systematic review..Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2018.12.031
Tagg JR, Dierksen KP (2003) Bacterial replacement therapy: adapting ‘germ warfare’ to infection prevention. Trends Biotechnol. https://doi.org/10.1016/S0167-7799(03)00085-4
Manti S, Parisi GF, Papale M, Licari A, Salpietro C, Miraglia Del Giudice M, Marseglia GL, Leonardi S (2020) Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for treatment of upper respiratory tract infections in children: a pilot study on short-term efficacy. Ital J Pediatr 46(1):42. https://doi.org/10.1186/s13052-020-0798-4
doi: 10.1186/s13052-020-0798-4
pubmed: 32245500
pmcid: 7126168
Passali D, Passali GC, Vesperini E, Cocca S, Visconti IC, Ralli M, Bellussi LM (2019) The efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a administered as nasal spray in the treatment of recurrent upper respiratory tract infections in children. Eur Rev Med Pharmacol Sci 23(1 Suppl):67–72. https://doi.org/10.26355/eurrev_201903_17352
doi: 10.26355/eurrev_201903_17352
pubmed: 30920629
Bidossi A, De Grandi R, Toscano M, Bottagisio M, De Vecchi E, Gelardi M, Drago L (2018) Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract. BMC Infect Dis 18(1):653. https://doi.org/10.1186/s12879-018-3576-9
doi: 10.1186/s12879-018-3576-9
pubmed: 30545317
pmcid: 6292094